208 related articles for article (PubMed ID: 37500934)
1. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
Au TY; Arudkumar J; Assavarittirong C; Benjamin S
Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
3. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
Xu L; Wang J; Liu Y; Xie L; Su B; Mou D; Wang L; Liu T; Wang X; Zhang B; Zhao L; Hu L; Ning H; Zhang Y; Deng K; Liu L; Lu X; Zhang T; Xu J; Li C; Wu H; Deng H; Chen H
N Engl J Med; 2019 Sep; 381(13):1240-1247. PubMed ID: 31509667
[TBL] [Abstract][Full Text] [Related]
5. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
[TBL] [Abstract][Full Text] [Related]
8. Biallelic, Selectable, Knock-in Targeting of CCR5
Scheller SH; Rashad Y; Saleh FM; Willingham KA; Reilich A; Lin D; Izadpanah R; Alt EU; Braun SE
Front Immunol; 2022; 13():821190. PubMed ID: 35386712
[TBL] [Abstract][Full Text] [Related]
9. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
[TBL] [Abstract][Full Text] [Related]
10. Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A; Paneerselvam N; Lawson BR
Clin Immunol; 2023 Oct; 255():109741. PubMed ID: 37611838
[TBL] [Abstract][Full Text] [Related]
11. Increased Efficiency for Biallelic Mutations of the
Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
[TBL] [Abstract][Full Text] [Related]
13. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
Lai Y
Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
[TBL] [Abstract][Full Text] [Related]
14. Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV.
Freen-van Heeren JJ
BioTech (Basel); 2022 Jul; 11(3):. PubMed ID: 35892930
[TBL] [Abstract][Full Text] [Related]
15. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
17. The Strategies and Challenges of CCR5 Gene Editing in Hematopoietic Stem and Progenitor Cells for the Treatment of HIV.
Karuppusamy KV; Babu P; Thangavel S
Stem Cell Rev Rep; 2021 Oct; 17(5):1607-1618. PubMed ID: 33788143
[TBL] [Abstract][Full Text] [Related]
18. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for HIV cure.
Kuritzkes DR
J Clin Invest; 2016 Feb; 126(2):432-7. PubMed ID: 26731468
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection.
Schmidt JK; Reynolds MR; Golos TG; Slukvin II
Retrovirology; 2022 Aug; 19(1):17. PubMed ID: 35948929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
